BPG is committed to discovery and dissemination of knowledge
Featured Articles
6/26/2026 10:03:12 AM | Browse: 4 | Download: 0
 |
Received |
|
2026-02-24 07:23 |
|
Peer-Review Started |
|
2026-02-24 07:25 |
|
First Decision by Editorial Office Director |
|
2026-03-17 10:16 |
|
Return for Revision |
|
2026-03-17 10:16 |
|
Revised |
|
2026-03-31 03:37 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2026-04-17 02:39 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2026-04-17 03:48 |
|
Articles in Press |
|
2026-04-17 03:48 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2026-06-16 01:01 |
|
Publish the Manuscript Online |
|
2026-06-26 09:50 |
| ISSN |
1948-5182 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
©Author(s) (or their employer(s)) 2026. No commercial re-use. See Permissions. Published by Baishideng Publishing Group Inc. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Review |
| Article Title |
Emerging treatment options for metabolic dysfunction-associated steatotic liver disease and its related liver diseases
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Chun-Ye Zhang and Ming Yang |
| Funding Agency and Grant Number |
|
| Corresponding Author |
Ming Yang, Assistant Professor, PhD, Department of Surgery, School of Medicine, University of Connecticut, 263 Farmington Avenue, Farmington, CT 06030, United States. minyang@uchc.edu |
| Key Words |
Metabolic dysfunction-associated steatotic liver disease; Metabolic dysfunction-associated steatohepatitis; Clinical trials; Molecular mechanisms; Treatments; Therapeutic strategies |
| Core Tip |
Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common type of chronic liver disease, affecting more than a quarter of the global population. MASLD is driven by many factors, including dietary and genetic factors. Without effective treatment, MASLD can lead to liver cirrhosis and cancer. Currently, treatment options for MASLD and metabolic dysfunction-associated steatohepatitis (MASH), an advanced form of MASLD, are limited. Ongoing clinical trials suggest that drug repurposing for metabolic disorders, dietary modifications, exercise, natural products, and combination therapies offer promising strategies for the management and treatment of MASLD and MASH. |
| Publish Date |
2026-06-26 09:50 |
| Citation |
Zhang CY, Yang M. Emerging treatment options for metabolic dysfunction-associated steatotic liver disease and its related liver diseases. World J Hepatol 2026; 18(6): 120178
|
| URL |
https://www.wjgnet.com/1948-5182/full/v18/i6/120178.htm |
| DOI |
https://doi.org/10.4254/wjh.120178 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
